BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs

Rhea-AI Summary

BioRestorative (NASDAQ:BRTX) announced that IP Australia allowed Patent Application No. 2020265664 on Feb. 24, 2026, covering non-naturally occurring 3D brown adipose-derived stem cell (BADSC) aggregates and methods of making them.

The allowance extends ThermoStem®'s Australian IP protection, focuses on an allogeneic, off-the-shelf BADSC platform for obesity and metabolic disorders, and signals continued global patent portfolio building for next-generation, cell-based alternatives to GLP-1 drugs.

Positive

• Australian patent allowance dated Feb 24, 2026
• Broad claim on 3D BADSC aggregates manufacturing method
• Strengthens ThermoStem® IP position for obesity/metabolic disorders

Negative

• Allowance currently limited to Australia
• Claims cover a manufacturing method, not therapeutic claims

Argus Feb 24 session

+37.01% close to close 47.3x rel. volume Open Argus

Details

News Market Reaction – BRTX

On Feb 24, the day this news came out, BRTX closed 37.01% above the previous close. That session’s volume was 47.3x the stock’s average daily volume.

Data tracked by StockTitan Argus for the Feb 24 session.

Key Figures

Patent application number: 2020265664

Patent application number

2020265664

IP Australia allowed patent application for ThermoStem® technology

Historical Context

5 past events · Latest: Feb 13

5 events

1. Feb 13

   Equity offering closed

   24h Move

   +16.1%

   Closed $5.0M public offering with shares and warrants at $0.35.

2. Feb 11

   Equity offering priced

   24h Move

   -35.4%

   Priced $5.0M offering of 14,285,715 Units at $0.35.

3. Feb 11

   Positive FDA meeting

   24h Move

   -35.4%

   Positive Type B FDA meeting on expedited BLA path for BRTX-100.

4. Feb 10

   Phase 2 enrollment complete

   24h Move

   -38.9%

   Completed enrollment of 99 patients in Phase 2 BRTX-100 cLDD trial.

5. Nov 17

   FDA meeting granted

   24h Move

   -6.8%

   FDA granted Type B meeting on potential accelerated BLA pathway.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

glp-1 drugs, cell-based therapeutic candidates, regenerative medicine, stem cell-based therapies, +4 more

8 terms

glp-1 drugs medical

"GLP-1 drugs have captured global attention, but they come with limitations"

GLP-1 drugs are medicines that mimic a natural gut hormone (glucagon-like peptide-1) to help lower blood sugar and reduce appetite, often used to treat type 2 diabetes and promote weight loss. They matter to investors because they can reshape demand across healthcare — affecting drug sales, medical costs, insurance coverage, and related industries — much like a disruptive new product that changes how people buy and use an everyday item.

cell-based therapeutic candidates medical

"BioRestorative believes its cell-based therapeutic candidates may offer the potential"

Living cells engineered or selected to treat or cure disease, offered as experimental treatments before full regulatory approval. Think of them like specialized repair crews sent into the body to replace, fix, or reprogram damaged parts; investors care because these candidates can unlock major medical advances and high future revenue but carry long development timelines, steep costs and regulatory risk that can dramatically affect a company’s value.

regenerative medicine medical

"a late stage clinical regenerative medicine innovator focused on stem cell-based"

A field of medical treatments that aims to repair, replace or regenerate damaged tissues and organs using approaches such as cell or gene therapies, engineered tissues, and biologically active materials. It matters to investors because successful regenerative therapies can create entirely new, high-value markets and replace chronic treatments, offering large potential returns but also long development timelines, heavy regulation and high technical risk—like betting on a promising new technology that could either revolutionize care or fail in trials.

stem cell-based therapies medical

"focused on stem cell-based therapies and products, today announced that IP Australia"

Therapies that use living stem cells as the active ingredient to repair, replace or regenerate damaged tissues or organs; think of them as planting seeds that can grow into new cells or structures inside the body. They matter to investors because they can address conditions with few existing treatments, offering large potential markets and high returns, but they also carry long development timelines, strict regulatory hurdles and clinical risk that can make outcomes binary and volatile.

intellectual property regulatory

"IP Australia, the intellectual property branch of the Australian government"

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

allogeneic medical

"allogeneic, off-the-shelf, brown adipose-derived stem cell (BADSC) ThermoStem"

Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.

off-the-shelf medical

"allogeneic, off-the-shelf, brown adipose-derived stem cell (BADSC) ThermoStem"

Off-the-shelf describes products, software, medical devices, or solutions that are commercially available and ready to use without custom design or development. Investors care because off-the-shelf items typically cost less and reach the market faster than bespoke alternatives, reducing project risk and expense; like buying a ready-made appliance instead of commissioning a custom-built one, they offer predictable performance and clearer regulatory and cost forecasts.

brown adipose-derived stem cell medical

"brown adipose-derived stem cell (BADSC) ThermoStem technology, designed to treat obesity"

Cells taken from brown fat tissue that can multiply and turn into different types of cells for use in research and therapy. Think of them like repairable building blocks harvested from a specific kind of body tissue; scientists test and develop them for potential treatments for metabolic and regenerative conditions. Investors track developments because successful therapies or manufacturing methods can create new drug candidates, licensing opportunities, or clinical milestones that affect company value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks. 
  
  
• BioRestorative believes its cell-based therapeutic candidates may offer the potential for longer-lasting efficacy with improved safety and dosing advantages.
  

MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced that IP Australia, the intellectual property branch of the Australian government, has allowed Patent Application No. 2020265664 titled, “Non-naturally occurring three-dimensional (3D) brown adipose-derived stem cell aggregates, and methods of generating and using the same.”

The newly allowed patent application provides the broadest protection obtained for BioRestorative’s allogeneic, off-the-shelf, brown adipose-derived stem cell (BADSC) ThermoStem^® technology, designed to treat obesity and metabolic disorders. The claims covered are: a method of making a non-naturally occurring three-dimensional brown adipose derived stem cell aggregate.

With this allowance, BioRestorative is further protected in its development of potential next-generation, cell-based alternatives to GLP-1 drugs, which continue to be one of the fastest-growing therapeutic categories in the world.

“As we continue our mission to advance cell-based therapeutic candidates that may offer the potential for longer-lasting efficacy with improved safety and dosing advantages over GLP-1 drugs, we remain focused on building our global patent protection to strengthen our competitive moat in obesity and related metabolic diseases, and on bolstering our position as a leader in the stem cell-based therapies and products space,” said Lance Alstodt, BioRestorative’s Chief Executive Officer. “I am proud of our team’s diligent work in securing patent protection across key markets, and adding this Australian patent application to our growing global IP portfolio underscores our commitment and belief in the incredible potential of ThermoStem^®.”

About BioRestorative Therapies, Inc.

BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform:

• Disc/Spine Program (brtxDISC^™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.

• Metabolic Program (ThermoStem^®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.

• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@biorestorative.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioRestorative (BRTX) announce on Feb. 24, 2026 regarding ThermoStem®?

They announced an allowed Australian patent application covering 3D brown adipose stem cell aggregates and their manufacture. According to the company, Patent Application No. 2020265664 was allowed by IP Australia to protect ThermoStem® technology.

How does the IP Australia allowance affect BioRestorative (BRTX) patent protection?

It extends ThermoStem® protection specifically in Australia, strengthening regional IP rights. According to the company, the allowance adds the broadest protection obtained so far for their allogeneic, off-the-shelf BADSC platform.

What exactly do the allowed claims for BRTX's Australian patent cover?

The claims cover a method of making a non-naturally occurring 3D brown adipose-derived stem cell aggregate. According to the company, permitted claims focus on the manufacturing method rather than therapeutic use claims.

Will the Australian patent allowance change ThermoStem®'s development plans for obesity treatments?

The allowance reinforces IP support for ThermoStem® development but does not itself alter clinical timelines. According to the company, the patent boosts their global portfolio while they continue advancing cell-based therapeutic candidates.

Does the allowed Australian patent mean global exclusivity for BioRestorative (BRTX)?

No; the allowance secures protection in Australia but not automatic global exclusivity. According to the company, this Australian allowance adds to a growing global IP portfolio rather than constituting worldwide patent grant.